Results 31 to 40 of about 34,994 (236)

Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer

, 2023
Systemic treatment received by patients prior to selective FGFR inhibitors, according to the detection of FGFR kinase domain mutations and/or PI3K/mTOR pathway alterations.
Rastislav Bahleda (16617234), Giorgia Guaitoli (16827105), Francesco Facchinetti (16827090), David Combarel (16827111), Stefan Michiels (9081965), Antoine Hollebecque (15010338), Yoann Pradat (15352227), Santiago Ponce-Aix (16827114), Sergey I. Nikolaev (15061686), Luc Friboulet (15025943), Lambros Tselikas (15019536), Ludovic Bigot (16617254), Juan David Florez Arango (16827102), Hayato Mizuta (16827108), Benjamin Besse (15061674), Damien Vasseur (16827096), Cédric Pobel (16617263), Olivier Déas (16827099), Floriane Braye (16827093), Ken A. Olaussen (16827117), Yohann Loriot (15123021), Jean-Yves Scoazec (15036392)   +21 more
core   +2 more sources

Fibroblast growth factor receptors as targets for anticancer therapy in cholangiocarcinomas and urothelial carcinomas

Heliyon, 2023
Cholangiocarcinomas and urothelial carcinomas are lethal tumors worldwide and only a minority of patients are eligible for surgery at diagnosis.
Demi Wekking, Andrea Pretta, Serafina Martella, Alessandra Pia D'Agata, Joanna Joeun Choe, Nerina Denaro, Cinzia Solinas, Mario Scartozzi   +7 more
doaj   +1 more source

Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer

npj Precision Oncology, 2021
Various genetic alterations of the fibroblast growth factor receptor (FGFR) family have been detected across a wide range of cancers. However, inhibition of FGFR signaling by kinase inhibitors demonstrated limited clinical effectiveness.
Ikuko Takeda Nakamura, Shinji Kohsaka, Masachika Ikegami, Hiroshi Ikeuchi, Toshihide Ueno, Kunhua Li, Tyler S. Beyett, Takafumi Koyama, Toshio Shimizu, Noboru Yamamoto, Fumiyuki Takahashi, Kazuhisa Takahashi, Michael J. Eck, Hiroyuki Mano   +13 more
doaj   +1 more source

Fibroblast growth factor receptor family mutations as a predictive biomarker for immune checkpoint inhibitors and its correlation with tumor immune microenvironment in melanoma

Frontiers in Immunology, 2022
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has significantly improved the clinical outcomes of patients with metastatic melanoma. However, survival benefits are only observed in a subset of patients.
Wengang Zhang, Handai Xia, Rui Yang, Yuqing Zhang, Qi Zheng, Xiaoling Shang, Ni Liu, Xinchun Ma, Chenxi Wei, Hang Chen, Xin Mu, Xiuwen Wang, Yanguo Liu   +12 more
doaj   +1 more source

FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors

, 2021
Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in solid malignancies, representing an attractive therapeutic target. In breast cancer, especially in estrogen receptor positive (ER+) subtype, FGFR signaling
Servetto A., Formisano L., Arteaga C. L.
core   +1 more source

Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling

Cells, 2021
Increasing evidence indicates that success of targeted therapies in the treatment of cancer is context-dependent and is influenced by a complex crosstalk between signaling pathways and between cell types in the tumor.
Harriet R. Ferguson, Michael P. Smith, Chiara Francavilla   +2 more
doaj   +1 more source

FGFR-1 is required by epicardium-derived cells for myocardial invasion and correct coronary vascular lineage differentiation [PDF]

, 2009
Critical steps in coronary vascular formation include the epithelial–mesenchyme transition (EMT) that epicardial cells undergo to become sub-epicardial; the invasion of the myocardium; and the differentiation of coronary lineages.
Pennisi, David J., Pennisi, D. J., Mikawa, Takashi, Mikawa, T   +3 more
core   +1 more source

Tackling FGFR Fusion-Positive Cancers with a Novel Synergistic Combination of FGFR and HDAC Inhibitors

, 2023
FGFR genomic alterations have been implicated in a number of cancers as oncogenesis driver genes. However, despite the approval of several FGFR inhibitors as targeted therapies for the treatment of cancer patients with FGFR aberrations in recent years ...
Wang, Zechen
core   +1 more source

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer

BMC Cancer, 2022
Background Mutations and fusions in Fibroblast Growth Factor Receptor 3 (FGFR3) occur in 10–20% of metastatic urothelial carcinomas and confer sensitivity to FGFR inhibitors. However, responses to these agents are often short-lived due to the development
Andrew J. Weickhardt, David K. Lau, Margeaux Hodgson-Garms, Austen Lavis, Laura J. Jenkins, Natalia Vukelic, Paul Ioannidis, Ian Y. Luk, John M. Mariadason   +8 more
doaj   +1 more source

βKlotho Inhibits Cell Proliferation by Downregulating ELK4 and Predicts Favorable Prognosis in Prostate Cancer

Cancer Management and Research, 2021
Changlin Mao,1 Wei Dong,2 Jiaju Lu,3 Zhao Zhang,4 Hongliang Wu,5 Armin Ghavamian,1 Dongbin Bi,3 Pei Gao,1 Zhao Liu,5 Sentai Ding1,3 1Department of Urology, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong ...
Mao C, Dong W, Lu J, Zhang Z, Wu H, Ghavamian A, Bi D, Gao P, Liu Z, Ding S   +9 more
doaj